ALIGN for Older Adults With Cancer in SNFs
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- University of Colorado, Denver
- Study ID
- NCT06616298
- Status
- Recruiting
Conditions
- Advanced Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 98 Years
- Healthy Volunteers
- Not accepted
Interventions
- Assessing and Listening to Individual Goals and Needs (ALIGN) — OTHERAssessing and Listening to Individual Goals and Needs (ALIGN). ALIGN utilizes the skills of palliative care social workers (PCSWs) trained in family and systems-level theory to address changing preferences for care, family distress, and to facilitate communication across care transitions to improve care aligned with preferences. A patient navigator supports the patient/caregiver and social worker dynamic by helping patients access care and resources. The intervention is implemented virtually in community SNFs and follows patients for 45 days after SNF discharge to reflect real-world patient flow.
Study Details
The goal of this clinical trial is to learn if it is possible to deliver a palliative care intervention called ALIGN (Assessing and Listening to Individual Goals and Needs) to hospitalized older adults with advanced cancer who are discharged to a skilled nursing facility and their caregivers. The main questions it aims to answer are: * Can the investigator successfully deliver the ALIGN intervention in different skilled community nursing facilities? * Can the investigator successfully collect information from participants throughout the study? * How can the investigator best prepare caregivers to make medical decisions for loved ones that become unable to do so themselves? Researchers will compare ALIGN to care as it is usually delivered. Participants will: * Visit virtually with an ALIGN palliative care social worker every 1-2 weeks during their skilled nursing facility stay and up to 45 days after discharge from the facility or will see a palliative care clinician if recommended by their oncologist or other involved clinician. * Participants will provide information about how they are doing 1 month, 3 months, and 6 months after enrolling in the study.
Key Dates
- Start date
- Feb 24, 2025
- Status verified
- Apr 2026
- Primary completion
- Aug 24, 2027
- Completion
- Aug 1, 2028
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Older patients with advanced cancerOlder adults with advanced cancer from the University of Colorado Hospital being discharged to skilled nursing facilities (SNF).
- Experimental: Caregivers of older patients with advanced cancerCaregivers of older adults with advanced cancer from the University of Colorado Hospital being discharged to skilled nursing facilities.
- No Intervention: Control ArmControl arm participants will receive enhanced usual care. Patients will be provided resources for advance care planning and interact with SNF staff and involved providers who may refer them to palliative care or hospice like previous rigorous palliative care trials.
Primary Outcome Measure
Intervention fidelity as assessed by fidelity checklist [ Time Frame: 2.5 years ]
Central Contacts
- Sarguni Singh, MD503.703.0797
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | Sarguni Singh, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Aurora, CO
Related Studies
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsPHASE1 · Recruiting · I-Mab Biopharma US Limited · Orange, California
- Psilocybin Therapy in Advanced CancerPHASE2/PHASE3 · Recruiting · NYU Langone Health · Aurora, Colorado
- A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815PHASE1 · Recruiting · Jazz Pharmaceuticals · Los Angeles, California